Key result
Finerenone reduces CV and kidney outcomes in CKD with T2D regardless of diuretic use.
Why the study?
Does finerenone reduce cardiovascular and kidney events in patients with chronic kidney disease and type 2 diabetes, and is this effect modified by baseline diuretic use?
RCT (n=12,990)
1:1
Yes
Does finerenone reduce cardiovascular and kidney events in patients with chronic kidney disease and type 2 diabetes, and is this effect modified by baseline diuretic use?
Answers are grounded in this paper and cite their sources.
Finerenone provides consistent cardiovascular and kidney benefits in patients with CKD and T2D regardless of baseline diuretic use, without an excess risk of severe hyperkalemia.
AIMS: This post hoc analysis aimed to assess the efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist finerenone by baseline diuretic use in FIDELITY, a pre-specified pooled analysis of the phase III trials FIDELIO-DKD and FIGARO-DKD. METHODS AND RESULTS: ) were randomized 1:1 to finerenone or placebo. Patients were analysed by baseline diuretic use (yes/no) and type of diuretic (loop or thiazide). Key efficacy outcomes included a cardiovascular composite (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) and a kidney composite (kidney failure, sustained ≥57% decrease in eGFR, or kidney-related death). Out of 12 990 patients, 51.6% were taking diuretics at baseline (21.6% loop; 24.2% thiazide diuretics). Finerenone reduced the risk of cardiovascular and kidney composite outcomes versus placebo; diuretic use did not modify this effect on the cardiovascular (p-interaction = 0.94) or kidney outcomes (p-interaction = 0.55). Hyperkalaemia incidences were similar between finerenone subgroups irrespective of diuretic use and lower with placebo versus finerenone (with diuretics: finerenone 13.7% vs. placebo 5.7%; without diuretics: 14.3% vs. 8.3%). The incidence of hyperkalaemia leading to hospitalization or study drug discontinuation was low across treatment groups irrespective of diuretic use. CONCLUSION: This analysis showed that the efficacy and safety of finerenone in patients with CKD and T2D was not modified by baseline diuretic use.
No takes yet. Share an insight, caveat, or question.
Mentz et al. (2025) conducted an RCT in Chronic Kidney Disease and Type 2 Diabetes (n=12,990). Finerenone vs. Placebo was evaluated on Cardiovascular composite (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) and a kidney composite (p=p-interaction = 0.94 (cardiovascular), 0.55 (kidney)). Finerenone reduced cardiovascular and kidney composite outcomes versus placebo in patients with CKD and T2D, with efficacy unmodified by baseline diuretic use.
Synapse has enriched 10 related papers. Consider them for comparative context: